Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotens…
Biotechnology
US, Deer Park [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Eton Pharmaceuticals, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2019 | -1.9900 | -1.147 | 0 | 1 | -12 | -29 | -10 | 0.55 | -10 | 0.58 | 4 | 78 |
| 2020 | -1.0200 | -1.275 | 0.96 | 1 | -18 | -32 | -18 | 0.55 | -18 | 0.58 | 7 | 78 |
| 2021 | -1.3700 | -0.080 | 0.04 | 23 | -28 | -2 | -26 | -11 | -27 | -11 | 12 | 1,571 |
| 2022 | -0.1200 | -0.380 | 21 | 21 | -2 | -9 | -1 | -10 | -1 | -10 | 14 | 1,470 |
| 2023 | -0.3900 | 0.010 | 21 | 32 | -9 | 0.26 | -6 | -15 | -8 | -15 | 18 | 2,158 |
| 2024 | -0.0365 | -0.135 | 31 | 37 | 0.94 | -3 | 0.29 | -17 | -1 | -18 | 18 | 2,555 |
| 2025 | - | 0.420 | - | 68 | - | 10 | - | -32 | - | -34 | - | 4,609 |
| 2026 | - | 2.F7X/td> | - | 2.F7X/td> | - | 2.F7X/td> | - | 2.F71/td> | - | 2.F71 | - | 2.F71 |
| 2027 | - | 1.F8X/td> | - | 1.F8X/td> | - | 1.F8X/td> | - | 1.F81/td> | - | 1.F81 | - | 1.F81 |
| 2028 | - | 0.F9X/td> | - | 0.F9X/td> | - | 0.F9X/td> | - | 0.F91/td> | - | 0.F91 | - | 0.F91 |